Articles related to NEOADJUVANT TREATMENT

Three-hundred-twenty-four (324) patients with stage II or III rectal adenocarcinoma were treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT). Patients then underwent total mesorectal excision (TME) or were assigned to a watch-and-wait status on the basis of tumor response. Three-year TME-free survival was 41% in the INCT-CRT group and 53% in the CRT-CNCT group. Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival.

In this trial of nivolumab + chemotherapy vs. chemotherapy alone, nivolumab prolonged EFS by nearly 11 months and improved the pathologic complete response rate more than tenfold. There was also a trend toward improved OS with nivolumab. The study also reported an EFS improvement with nivolumab in both squamous and non-squamous NSCLC. Grade 3-4 treatment-related adverse events occurred in 34% of patients in the nivolumab arm and 37% of those in the chemotherapy-alone arm.